Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?
Where next in immunotherapy and melanoma?
Date
09 Oct 2016Session
Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?Presenters
Paolo AsciertoAuthors
P.A. AsciertoAuthor affiliations
- Unit Of Melanoma, Cancer Immunotherapy And Innovative Therapy, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Introduction
Presenter: Rolf A. Stahel
Session: Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?
Resources:
Webcast
Where next in targeted therapies and melanoma?
Presenter: Richard Marais
Session: Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?
Resources:
Slides
Patient advocacy initiatives
Presenter: Bettina Ryll
Session: Joint Symposium ESMO-EORTC-EACR: What has melanoma taught us about targeted therapies and immunotherapy?
Resources:
Slides
Webcast